List of Excipients in Branded Drug ADVIL DUAL ACTION WITH ACETAMINOPHEN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Haleon US Holdings LLC	ADVIL DUAL ACTION WITH ACETAMINOPHEN	ibuprofen, acetaminophen	0573-0145	CARNAUBA WAX
Haleon US Holdings LLC	ADVIL DUAL ACTION WITH ACETAMINOPHEN	ibuprofen, acetaminophen	0573-0145	CROSCARMELLOSE SODIUM
Haleon US Holdings LLC	ADVIL DUAL ACTION WITH ACETAMINOPHEN	ibuprofen, acetaminophen	0573-0145	FERRIC OXIDE RED
Haleon US Holdings LLC	ADVIL DUAL ACTION WITH ACETAMINOPHEN	ibuprofen, acetaminophen	0573-0145	GLYCERYL DIBEHENATE

Advil Dual Action With Acetaminophen: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 10, 2026

Advil Dual Action with Acetaminophen combines ibuprofen 125 mg and acetaminophen 250 mg in one oral caplet. Haleon positions the product for temporary relief of minor aches and pains through two pharmacologically distinct active ingredients. The commercial opportunity is concentrated in dose convenience, differentiated immediate-release performance, child-resistant packaging, private-label competition, and reformulations that improve swallowability, stability, and manufacturing economics.

The product’s main technical constraint is excipient compatibility. Ibuprofen is a weak acid with poor aqueous solubility, while acetaminophen has higher solubility but can create dose, compression, and stability challenges at a 2:1 acetaminophen-to-ibuprofen ratio. An effective excipient platform must support rapid dissolution of both actives without increasing tablet size, friability, moisture sensitivity, or gastrointestinal tolerability concerns.

What is Advil Dual Action with Acetaminophen?

Advil Dual Action with Acetaminophen is an over-the-counter analgesic containing two active ingredients:

Product attribute	Publicly reported information
Brand	Advil Dual Action with Acetaminophen
Marketer	Haleon US Holdings LLC
Active ingredients	Ibuprofen 125 mg and acetaminophen 250 mg
Dosage form	Oral caplet
Therapeutic category	Analgesic and antipyretic
Intended population	Adults and children 12 years and older
Labeled dosing	Two caplets every eight hours as needed
Maximum labeled dose	Six caplets in 24 hours
Maximum daily active dose at label maximum	Ibuprofen 750 mg and acetaminophen 1,500 mg
FDA status	OTC analgesic product marketed under FDA requirements applicable to the active ingredients and product presentation

The product combines an NSAID, ibuprofen, with a non-NSAID analgesic and antipyretic, acetaminophen. The label warns consumers against taking the product with other acetaminophen-containing medicines or other NSAIDs, including aspirin, naproxen, and additional ibuprofen products.[1]

What excipients are used in Advil Dual Action with Acetaminophen?

The product’s public labeling identifies inactive ingredients used to form, coat, color, stabilize, and process the caplet. Public product labels should be treated as the controlling source for the marketed excipient list because formulations can change by manufacturing site, presentation, or label revision.[1]

Typical functional categories relevant to the product include:

Excipient function	Commercial role in the caplet
Diluent or filler	Provides tablet mass and supports content uniformity
Binder	Improves granule and tablet mechanical strength
Disintegrant	Promotes tablet breakup after ingestion
Lubricant	Reduces ejection force and tooling friction
Glidant	Improves powder flow during compression
Film coating polymer	Protects the tablet and improves swallowability
Plasticizer	Reduces coating brittleness
Opacifier and colorant	Provides product identification and light protection
Surfactant or wetting aid	Supports wetting and dissolution of ibuprofen
Printing or coating aid	Supports branding and handling

A generic or private-label developer should not assume that reproducing the listed excipients reproduces the reference product. Performance depends on excipient grade, particle size, granulation route, lubricant level, compression force, coating weight, and dissolution conditions.

How does the ibuprofen-acetaminophen combination affect excipient selection?

Ibuprofen is the more difficult active from a dissolution perspective. Its poor water solubility can slow release from a conventional compressed tablet. Acetaminophen is more soluble but occupies substantial tablet mass at 250 mg per caplet. The formulation therefore needs to balance dissolution acceleration against tablet size and manufacturability.

Ibuprofen dissolution strategy

Potential excipient approaches include:

• Wetting agents or surfactants to improve contact between ibuprofen particles and gastrointestinal fluid.
• Smaller ibuprofen particle size to increase surface area.
• Coprocessed fillers that improve liquid penetration.
• Superdisintegrants that create rapid caplet breakup.
• Solid dispersion or amorphous dispersions for higher-performance products, subject to stability control.
• Liquisolid or lipid-based approaches for differentiated products, although these can complicate scale-up and tablet hardness.

A standard immediate-release product does not require the most aggressive solubility-enhancement technology. The commercial objective is usually rapid and reproducible release at a cost compatible with a high-volume OTC product.

Acetaminophen processing strategy

Acetaminophen can present compression and capping problems, especially when the formulation uses a high active load. Direct compression grades, engineered particle morphology, dry granulation, or wet granulation can improve flow and tablet strength.

The excipient system should limit:

• Capping and lamination.
• Excessive tablet weight.
• Slow disintegration caused by over-lubrication.
• Moisture-related degradation.
• Segregation between acetaminophen and ibuprofen particles.

Compatibility and stability

The formulation should be evaluated for:

• Moisture uptake.
• Ibuprofen-acetaminophen interaction under accelerated storage.
• Color change.
• Coating integrity.
• Dissolution after storage.
• Active-content uniformity.
• Extractables and leachables from packaging.
• Stability under high humidity and elevated temperature.

Blister packaging can provide stronger moisture protection than some bottle systems, but bottles may offer lower packaging cost and better consumer convenience. Desiccants, high-barrier films, induction seals, and moisture-resistant coatings can be commercially relevant formulation and packaging choices.

What formulation patents could protect an ibuprofen-acetaminophen product?

Formulation patents can protect more than the active-ingredient combination. Potential claim categories include:

1. Specific ibuprofen and acetaminophen ratios.
2. Immediate-release caplet structures.
3. Bilayer or multilayer tablets.
4. Granules containing one active ingredient separately from the other.
5. Particle-size distributions.
6. Solid dispersions or amorphous ibuprofen systems.
7. Specific dissolution profiles.
8. Coating compositions and coating weights.
9. Taste-masking systems.
10. Packaging systems that control moisture or oxygen exposure.
11. Manufacturing processes that improve content uniformity or tablet strength.

A layered tablet could place ibuprofen and acetaminophen in separate zones, allowing independent control of disintegration and dissolution. A co-granulated formulation could simplify manufacturing but may increase compatibility and stability risks. Separate granulation may provide stronger process control at a higher manufacturing cost.

Public labeling identifies the marketed composition but does not, by itself, establish the existence, scope, validity, or enforceability of formulation patents. A complete patent-clearance analysis requires review of patent databases, assignment records, prosecution histories, and litigation filings.

What is the Orange Book status of Advil Dual Action with Acetaminophen?

The FDA Orange Book is primarily a reference for approved prescription and certain listed drug products, therapeutic equivalence evaluations, patent certifications, and exclusivity information.[2] OTC analgesic products marketed under applicable OTC regulatory pathways do not necessarily present the same Orange Book patent-listing profile as prescription NDA products.

For Advil Dual Action with Acetaminophen, the principal commercial barriers are more likely to arise from:

• Brand recognition.
• Retail placement.
• Advertising scale.
• Formulation know-how.
• Manufacturing economics.
• Packaging and supply-chain execution.
• Trademark and trade-dress rights.
• Regulatory compliance.

A competitor should not infer freedom to operate solely from the absence of an obvious Orange Book patent listing. Patent rights can exist outside the Orange Book, including formulation, process, packaging, trademark, and design rights.

When does Advil Dual Action with Acetaminophen lose exclusivity?

The product does not have a single practical exclusivity date comparable to a newly approved prescription drug with five-year new chemical entity exclusivity. OTC market entry is generally constrained by regulatory compliance, intellectual property, manufacturing capability, and commercial execution rather than one expiration event.

The active ingredients are long-established. The commercial exclusivity of the branded combination therefore depends on product-specific rights and market advantages, not new-molecule exclusivity.

Exclusivity category	Relevance to Advil Dual Action
New chemical entity exclusivity	Not applicable to ibuprofen or acetaminophen
Prescription-style five-year exclusivity	Not the central market barrier
OTC monograph or OTC regulatory compliance	Core entry requirement
Formulation patents	Potentially relevant if valid and enforceable
Process patents	Potentially relevant to manufacturing methods
Trademark rights	Important to the Advil brand
Trade dress	May affect packaging and visual imitation
Data or approval-related rights	Product-specific and dependent on regulatory pathway
Retail and advertising advantages	Major practical barrier

The absence of a single exclusivity date creates an open-ended competitive environment. A generic or store-brand producer can enter once it has a compliant formulation, appropriate labeling, acceptable quality systems, and a commercially viable supply chain, subject to applicable intellectual property rights.

Which companies are challenging Advil Dual Action with Acetaminophen?

The most credible competitors are likely to come from three groups:

Branded analgesic companies

Tylenol, Motrin, Bayer, and other analgesic brands compete for overlapping pain-relief demand. Their products may use a single active ingredient, different strengths, or alternative combinations.

Store brands and private labels

Retail pharmacies, mass merchants, warehouse clubs, and online retailers can market ibuprofen-acetaminophen combination products under private labels. These products can compete primarily through lower price and shelf placement.

Generic manufacturers

Large OTC manufacturers and contract manufacturers can produce compliant combination caplets for retailers or distributors. The technical entry barrier is moderate because the active ingredients are established and the dosage form is conventional, but robust dissolution, stability, and content uniformity remain essential.

A direct competitor may not need to duplicate the Advil formulation. A functionally equivalent excipient platform can support a therapeutically comparable product while reducing patent and trade-secret exposure.

What excipient opportunities exist for generic and private-label products?

The strongest commercial opportunities are tied to cost reduction and measurable consumer benefits.

Smaller, easier-to-swallow caplets

A high-load formulation using higher-density excipients, optimized granulation, or multilayer compression could reduce caplet volume. Smaller size can improve adherence and consumer acceptance, particularly for repeated dosing.

Faster disintegration

A superdisintegrant system, optimized pore structure, or improved wetting can support rapid tablet breakup. Any performance claim must be supported by dissolution and, where required, regulatory data.

Gastrointestinal tolerability

Excipient selection cannot eliminate the inherent risks associated with ibuprofen. It may, however, reduce local tablet persistence or improve dispersion. Claims about lower gastrointestinal impact would require substantial evidence and careful regulatory review.

Better moisture protection

High-barrier blister packs, desiccant-containing bottles, and moisture-resistant film coatings can protect dissolution performance and appearance during distribution.

Pediatric-friendly alternatives

The current caplet is directed to adults and children 12 years and older. A lower-dose chewable, orally disintegrating tablet, liquid, or mini-tablet could target different age groups, but such products would require careful dosing, palatability, safety, and labeling analysis.

Sustainable excipient systems

Manufacturers can reduce material use through lower coating weights, optimized tablet density, and packaging redesign. Replacing certain synthetic polymers or reducing solvent-intensive coating processes may support sustainability claims, but the product must maintain performance and stability.

How strong is the patent estate for Advil Dual Action with Acetaminophen?

The practical patent strength appears more likely to reside in formulation-specific or manufacturing claims than in the basic active-ingredient combination. Ibuprofen and acetaminophen are established compounds, and the broad concept of combining them is unlikely to provide durable composition-of-matter exclusivity.

Patent strength should be assessed across five dimensions:

Factor	Assessment
Active-ingredient novelty	Low
Combination concept	Potentially limited unless tied to narrow dosing or performance parameters
Formulation protection	Potentially meaningful
Manufacturing protection	Potentially meaningful where process conditions are difficult to design around
Brand and trade dress	Commercially important but separate from pharmaceutical patent scope

Narrow formulation claims may have value if they cover a commercially important dissolution profile, stability advantage, reduced tablet size, or manufacturing process. Their enforceability depends on claim construction, written description, enablement, prosecution history, prior art, and evidence of infringement.

What generic launch risks exist for Advil Dual Action?

A generic launch would usually involve a conventional immediate-release caplet containing the same active ingredients and strengths. Key risks include:

• Failure to match dissolution performance.
• Inadequate stability under OTC distribution conditions.
• Content uniformity problems caused by segregation.
• Excessive tablet size.
• Capping or lamination during high-speed compression.
• Infringement of formulation or process claims.
• Confusingly similar packaging.
• Incorrect warnings relating to acetaminophen and NSAID use.
• Retailer reluctance to substitute or stock an unknown brand.
• Supply constraints for pharmaceutical-grade ibuprofen and acetaminophen.

The most probable market-entry model is a private-label or authorized contract-manufacturing launch rather than a conventional prescription Paragraph IV campaign. Paragraph IV certification is relevant to listed patents for ANDA products, but it is not the default pathway for every OTC combination analgesic. A competitor would need to evaluate the applicable FDA pathway and any listed product-specific patents before selecting an ANDA or other regulatory strategy.[2]

What patent litigation and settlement issues affect the product?

No broad, product-defining patent litigation or settlement framework should be assumed from the brand name alone. OTC analgesic disputes more commonly involve:

• Trademark infringement.
• False or misleading comparative advertising.
• Trade-dress disputes.
• Formulation patent enforcement.
• Contract manufacturing disputes.
• Product liability claims.
• Regulatory challenges to labeling or marketing claims.

A Paragraph IV settlement would be commercially relevant only if a competitor pursued an ANDA involving a listed patent and the patent holder asserted infringement. In the absence of such a dispute, market entry is governed primarily by formulation development, FDA compliance, intellectual property clearance, and commercial access.

How does Advil Dual Action compare with single-ingredient analgesics?

Product type	Main advantage	Main limitation	Excipient opportunity
Ibuprofen-only product	Familiar NSAID profile and lower active load	NSAID-related warnings and contraindications	Faster dissolution, smaller tablets
Acetaminophen-only product	Broad consumer familiarity and no NSAID mechanism	Liver toxicity risk at excessive doses	Palatability, lower tablet weight
Ibuprofen-acetaminophen combination	Two mechanisms in one caplet	More complex warnings and active-ingredient management	Dual-release control, compact dosage form
Liquid combination product	Flexible dosing and easier swallowing	Stability, taste, packaging, and dosing complexity	Taste masking and preservative systems
Chewable combination product	Convenience for selected users	Strong taste and texture challenges	Flavor systems and grittiness control

The combination product can command a price premium over single-ingredient products if consumers perceive stronger or broader pain relief. The premium is vulnerable to private-label substitution because the active ingredients are well known and the dosage form is technically conventional.

What are the commercial opportunities for excipient suppliers?

Excipient suppliers can target the product category with platforms rather than single ingredients. The most commercially relevant offerings include:

• Direct-compression systems for high-active-load caplets.
• Co-processed fillers and disintegrants.
• Ibuprofen wetting and dissolution-enhancement systems.
• Low-moisture granulation technologies.
• High-density excipients for smaller tablets.
• Functional film coatings with improved moisture resistance.
• Color and coating systems that support brand differentiation.
• Continuous-manufacturing-compatible excipient blends.
• Sustainable coating and packaging materials.

The strongest value proposition is a documented reduction in manufacturing cost or a measurable improvement in dissolution, stability, tablet size, or line speed. Excipient suppliers with comparative data against common formulation platforms have an advantage in contract development and private-label bids.

Key Takeaways

• Advil Dual Action with Acetaminophen contains ibuprofen 125 mg and acetaminophen 250 mg per caplet.
• The primary formulation challenge is achieving rapid, reproducible ibuprofen dissolution while maintaining compact tablet size and strong compression performance.
• Excipient opportunities include wetting systems, superdisintegrants, high-density fillers, moisture-resistant coatings, and engineered granulation platforms.
• The product is unlikely to have new-molecule exclusivity because both active ingredients are established.
• Formulation, manufacturing, packaging, trademark, and trade-dress rights may remain relevant even where no obvious Orange Book barrier applies.
• Private-label and generic entry risks are moderate from a technical perspective and higher from a commercial perspective.
• A smaller caplet, faster-dissolving product, pediatric presentation, or improved moisture-protection system could create differentiated commercial positions.
• Generic developers should focus on dissolution matching, stability, content uniformity, label compliance, and non-infringing formulation design.

FAQs About Advil Dual Action Excipient Strategy

Can a generic manufacturer use the same inactive ingredients as Advil Dual Action?

Yes, subject to regulatory compliance and intellectual property clearance. Matching the ingredient names is not enough. The developer must match critical quality attributes, including dissolution, hardness, friability, stability, and content uniformity.

Is Advil Dual Action an extended-release product?

The marketed caplet is positioned as an immediate-release analgesic product. A sustained-release or biphasic version would be a different formulation and could create separate regulatory, patent, and clinical considerations.

Can a manufacturer replace the film coating without changing the product?

A coating change may be possible if it preserves product quality, stability, appearance, dissolution, and labeling compliance. The change can still require regulatory assessment and intellectual property review.

Could a bilayer tablet compete with Advil Dual Action?

Yes. A bilayer structure could separate ibuprofen and acetaminophen granules, optimize each active’s release environment, and potentially reduce formulation interaction. It would also add compression, equipment, validation, and cost complexity.

What is the most attractive commercial reformulation?

A compact, rapid-disintegration caplet with improved moisture protection is likely the most practical opportunity. It addresses manufacturing and consumer-use factors without requiring a fundamentally different delivery system.

References

1. DailyMed. (n.d.). Advil Dual Action with Acetaminophen: Drug facts and labeling information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (n.d.). Drug facts label for over-the-counter analgesic and antipyretic products. https://www.fda.gov/drugs/understanding-over-counter-medicines

4. U.S. Food and Drug Administration. (2022). Acetaminophen: Avoiding serious risks from overdose. https://www.fda.gov/drugs/information-drug-class/acetaminophen

5. U.S. Food and Drug Administration. (n.d.). Nonsteroidal anti-inflammatory drugs and related labeling information. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/non-steroidal-anti-inflammatory-drugs-nsaids-selector